you, to update Oxbryta. on the afternoon, provide launch excited an Jeff. Good everyone. I'm of Thank
had an we As Ted mentioned, quarter. exceptional first
environment were able minimize to proud transition are disruption and launch. a to we escalated, working potential COVID-XX we quickly As the virtual that to
affairs IT take I'd all operations, our teams, of a like them and virtual moment to to support work interactions. our field marketing, and to enable recognize medical tirelessly
you Oxbryta, percent into the Oxbryta, covered the our underlying adoption; metrics three payer patient prescribing give coverage and metrics to informs I'd of which care health number Today, prescriptions like combined share new lives. insight revenues demand; progress. further captures which we're providers progress in with net [indiscernible] will These that of making for are:
during for total time GBT We since vast quarter and needs. support Source, majority support into approximately prescriptions new our that X,XXX Oxbryta enrollments provides real education wide launch. were the each patients Firstly customized prescribed practical on and approximately first range program of patient's of that's of patient The prescriptions. support, saw financial high-touch a X,XXX a putting
patients generally receiving of encouraged patients we're coverage process, Oxbryta. is interest of who provide whose also to as coverage eligible assistance secure new in this In payer well free exceptions for these The medicine it's and medical patients as coverage We're patients, provided positive believe insurance activity received program. patient level the currently while include through unable drugs insurance not prescription a have exception. established. in and free under to medical are is to They by without indicative able early the our cases, include
cell sickle patient better in to understand them. order physicians, we're and hematologists the secured insurance dynamics we it has interactions. GBT of surveyed to approximately In April, that through XX on as patient for the relates process moved team force impact and disease Source practices, And successfully pleased COVID-XX primarily practice on coverage sales
using to encouraged phone that either telemedicine, of of video. than practices were see are some more We or form XX%
to We prescribing see visit. also treatment some that most without are any cell XX% physicians comfort live encouraged sickle new chronic of report nearly a disease level having
of XX% prescribed surveyed visit. a those having fact, In reported following Oxbryta virtual
the And This across reinforces what of decrease as report hand, volume, overall experiencing surveyed the result, in disease practices medical cell physicians COVID-XX that decline reduction On patient a patient nearly we're daily new a a volumes. seeing industry, other began. hence XX% the the prescriptions. majority in a of are sickle in pandemic
peak weekly we XX% in the decrease Specific a as in Oxbryta seen to have as from March. early new much prescriptions for GBT,
of rate quarter remain and to as new quarter progresses the the expect continue longer. We the second third potentially through prescriptions lower to
However, new this time, week. during we each prescriptions to see we encouraged that are even continue
about for long-term remain As potential confident the Oxbryta. such, we
to the were engage to Turning receptive practices Feedback to and from second half health provider majority first the team person are of virtual the transition quarter March continue to interactive The field in in due interactions indicates physicians. of we before actively to our survey virtual with for discussions. many care penetration, that the COVID-XX. conducted
video phone In fact, sales reps. the survey and in by engagements are with showed participating many physicians
We've created as for to sharing continue and practices new across our and as to regularly necessary. our and material learnings prepared these existing materials adapted virtual with We virtual are teams long support interactions interactions. best are
trial patients launching I'm materials launched also the digital recently pleased on our our hemoglobin a campaign and on polymerization. campaign these marketing support marketing and its We've coming campaign our with and about The it that FDA effects provider we feedback branded anticipate availability new received patient to critical months. have branded educate in to of come time our at care physicians. interaction help health
cell updated above XX%. among market of Based research that on aided we're encouraged awareness top Oxbryta specialists remains sickle
X they in will indicating next within initiate of Oxbryta interest physicians over strong and see in Oxbryta to indicating plan XX% practice use the Oxbryta almost continue XX% we Additionally, months. with they to their
March, and reached care overall XX% targeting of decile providers, of United our XX% reached approximately highest our we're therapeutic health nearly approximately have the Through States. specialists X,XXX the physicians in
Our launch. target average an decibel has high and since customer our of have team interactions nearly XX,XXX had at visited Xx total
approximately a written result, during XXX a prescription unique As care drug the first Oxbryta have of health providers quarter.
of providers since launch. For prescribing approximately unique a health total care XXX
As encouraged that are But care hematologists. we're a and prescribing Oxbryta. expected, percentage the majority pediatricians prescribers are primary of of also growing physicians
prescribers have prescriptions, the prescribers since prescriber decrease slowed. also per prescriptions Importantly, new of COVID-XX, three Oxbryta averaging with number has the written approximately of launch. multiple prescriptions in Consistent since new
our and long-term monitor We launch adjust plans accordingly. continue to to impact will potential any assess to
Consistent scheduled to meetings pandemic. for our place XX% covered expectations, with have meetings, as already representing able payers continue pleased we of payers. were now reimbursement Regarding coverage been have in We're Oxbryta lives. which COVID-XX payer virtual many with before that officially of we
coverage have X% lives, Medicare X% XX% we lives. representing of Medicaid place Specifically, lives of of in commercial and
the priority Fee-for-service This states. Medicaid Notably, plans given picture is we plans step an have in with the states. centralized coverage that secured the Medicaid the have influence a of coverage on Fee-for-service the the in XX overall XX important policies
Texas examples now sickle with cell states good Medicaid and of key Fee-for-service York two large populations are are covering that Oxbryta. in New
process. note not covering formulary, In medical Oxbryta addition, on it's yet that are patients if to through important the even exceptions many payers is
on made the our track continue are we obtaining coverage meet by the we of most complete to with remain We progress and We year. will we of meetings of first have half to payer pleased payers. the during XXXX, with believe the broad end goal
the I will update development over to pipeline. an Ted activities call clinical to on turn and now provide our
